Ginkgo Bioworks (NYSE: DNA) has given investors a lot of hope that the business can generate significant growth in the future. But that hasn't panned out just yet. In the meantime, the company has been burning through cash and incurring huge losses.

However, the cell programming company has been partnering with many top healthcare companies to help with drug discovery and biologic manufacturing, which should unlock growth opportunities down the road.

Management recently provided investors with an encouraging update about its operations, but is there enough of a reason to invest in this beaten-down stock, which has fallen by 82% since 2022?

Continue reading

Source Fool.com